期刊文献+

复方丹参滴丸对急性冠脉综合征患者CRP及血管内皮功能的影响 被引量:18

Effect of Fufangdanshendiwan on C-reactive Protein and Endothelium-dependent Vasodilatation in Patient with Acute Coronary Syndrome
下载PDF
导出
摘要 目的:观察复方丹参滴丸对急性冠脉综合征(CAS)患者C反应蛋白(CRP)及血管内皮功能的影响。方法:93例CAS患者随机分成治疗组47例,对照组46例。各组均以硝酸甘油、长效消心痛片、肠溶阿司匹林片、速避凝针、有溶栓指征者以尿激酶;治疗组在上述治疗的基础上,以复方丹参滴丸两组均于治疗前后1个月,用酶法测定甘油三脂(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)浓度,测定血清C反应蛋白(CRP)、一氧化氮(NO)、内皮素(ET),检测两种治疗方法对患者肱动脉血管内皮依赖性舒张功能(FMD)的影响。结果:治疗前两组各参数无明显著异(P>0.05)。治疗1个月后与治疗前相比,治疗组和对照组的CRP、ET水平均明显下降,NO水平升高(P<0.05或P<0.01),且治疗后两组比较有显著差异(P>0.05);治疗组的TG、TC、HDL-C、LDL-C均下降,FMD升高(P<0.05),而对照组无明显变化(P>0.05),两组比较有显著差异(P<0.05)。结论:复方丹参滴丸可以抑制炎症反应,稳定粥样斑块,改善血管内皮功能,减少CAS的发生。 Objective:To investigate the effect of Fufangdanshendiwan on C-reactive protein(CRP) and endothelium-dependent vasodilatation in patient with acute coronary syndrome(ACS).Method:93 cases ACS patients randomly divided into 2 groups with 47 in the cure group and 46 in the control group:the cure group were treated with Fufangdanshendiwan,10 pill three times a day,orally taken,in addition to routine therapy of ACS and the control group were treated with routine therapy of ACS alone.The changes of plasma triglyeeride(TG),total cholesterol(TC),high density liproteins cholesterol(HDL-C),low density liproteins cholesterol(LDL-C),C-reactive protein,endothelia(ET),nitric oxide(NO)and endothelium-dependent vasodilatation were measured in both groups before and after the treatment.Result:the blood levels of CRP,ET obviously decreased and the level of NO increased in both groups compared with that before treatment( P <0.05 or P <0.01)and the difference between the two groups was significant( P <0.05);the blood level of TG,TC,HDL-C,LDL-C decreased and endothelium-dependent vasodilatation increased significantly in the cure group( P <0.05).But there were no significant differences in control group ( P> 0.05).Conclusion:Fufangdanshendiwan can relieve inflammatory reaction,stabilize atherosclerotic plaque,improve endothelium-dependent vasodilatation and reduce the occurrence of ACS.
出处 《浙江中医学院学报》 2005年第4期13-15,共3页 Journal of Zhejiang College of Traditional Chinese Medicine
关键词 复方丹参滴丸 急性冠脉综合征 血管内皮功能 C反应蛋白 中药制剂 Fufangdanshendiwan,acute coronary syndrome,C-reactive protein,function of endothelium-dependent vasodilatation
  • 相关文献

参考文献7

二级参考文献51

  • 1罗向东 杨宗成 等.简便、灵敏的一氧化氮间接测定法[J].中华创伤杂志,1994,10:185-185.
  • 2[1]Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med,1999,340:115-126.
  • 3[2]Anderson J L, Carlquist J F, Joseph B, et al. Evaluation of C-reactive protien, an inflammatory marker, and infectious serology as risk factor for coronary artery disease and myocardial infarction. JACC,1998,32:35-35.
  • 4[3]Haverkate F, Thompson S G, Pyke S D M, et al. Production of C-reactive protien and risk of coronary events in stable and unstable angina: European concerted action on thrombosis and disabilities angina pectoris study group. Lancet, 1997,349:462-462.
  • 5[1]Pederson JR,Olsson AG,Faergeman V,et al.Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)[J].Circulation,1998,97:1453-1460.
  • 6[2]Flaker GC,Warnica JW,Sacks FW,et al.For the Cholesterol and Recurrent Event (CARE) investigators.Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations[J].J Am Coll Cardiol,1999,34:106-112.
  • 7[3]Downs JR,Clearfield M,Wies S,et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study[J].JAMA,1998,299:1615-1621.
  • 8[4]Kinlay S.Early statin therapy in acute coronary syndromes[J].Minerva cardioangiol,2003,51(5):577-584.
  • 9[5]Huggins GS,Pasternak PC,Alpert NM,et al.Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse[J].Circulation,1998,98:1291-1296.
  • 10[6]Inoue T,Hayashi M,Takayanagi K,et al.Lipid-lowering therapy with fluvastain inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients[J].Atherosclerosis,2002,160(2):369-376.

共引文献103

同被引文献220

引证文献18

二级引证文献169

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部